These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 29151134)

  • 1. KIT D816V- chronic myelomonocytic leukemia progressing to KIT D816V+ associated to mast cell leukemia responding to allogeneic hematopoietic cell transplantation.
    Prats-Martín C; Jiménez-Guerrero P; Morales-Camacho RM; Caballero-Velázquez T; Vargas MT; Pérez O; Montero I; Falantes J; Burillo-Sanz S; Carrillo E; Borrero JJ; Bernal R; Pérez-Simón JA
    Ann Hematol; 2018 Mar; 97(3):533-535. PubMed ID: 29151134
    [No Abstract]   [Full Text] [Related]  

  • 2. The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis.
    Erben P; Schwaab J; Metzgeroth G; Horny HP; Jawhar M; Sotlar K; Fabarius A; Teichmann M; Schneider S; Ernst T; Müller MC; Giehl M; Marx A; Hartmann K; Hochhaus A; Hofmann WK; Cross NC; Reiter A
    Ann Hematol; 2014 Jan; 93(1):81-8. PubMed ID: 24281161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aleukemic mast cell leukemia with abnormal immunophenotype and c-kit mutation D816V.
    Noack F; Sotlar K; Notter M; Thiel E; Valent P; Horny HP
    Leuk Lymphoma; 2004 Nov; 45(11):2295-302. PubMed ID: 15512820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation.
    Gotlib J; Berubé C; Growney JD; Chen CC; George TI; Williams C; Kajiguchi T; Ruan J; Lilleberg SL; Durocher JA; Lichy JH; Wang Y; Cohen PS; Arber DA; Heinrich MC; Neckers L; Galli SJ; Gilliland DG; Coutré SE
    Blood; 2005 Oct; 106(8):2865-70. PubMed ID: 15972446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects.
    Gleixner KV; Mayerhofer M; Aichberger KJ; Derdak S; Sonneck K; Böhm A; Gruze A; Samorapoompichit P; Manley PW; Fabbro D; Pickl WF; Sillaber C; Valent P
    Blood; 2006 Jan; 107(2):752-9. PubMed ID: 16189265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A case report of systemic mastocytosis associated with multiple hematologic non-mast cell lineage diseases.
    Grifoni FI; Sciumè M; Pravettoni V; Ulivieri FM; Muratori S; Fracchiolla NS; Tagliaferri E; Gianelli U; Migliorini AC; Cro L; Pacilli A; Mannelli F; Baldini L
    Hematol Oncol; 2019 Apr; 37(2):205-211. PubMed ID: 30849188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid engraftment of mast cells of donor origin in a case of acute myeloid leukemia with mast cell leukemia after allogeneic stem cell transplantation.
    Chen TY; Chen JS; Huang WT; Su WC; Tsao CJ
    Bone Marrow Transplant; 2003 Jul; 32(1):111-4. PubMed ID: 12815487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The upregulation of Pim kinases is essential in coordinating the survival, proliferation, and migration of KIT D816V-mutated neoplastic mast cells.
    Park H; Kim D; Koh Y; Yoon SS
    Leuk Res; 2019 Aug; 83():106166. PubMed ID: 31203104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute myeloid leukemia arising after Hodgkin lymphoma in a patient with WHIM syndrome.
    Zhang A; Chen X; Li Z; Ruan M; Zhang Y; Zhu X
    Pediatr Blood Cancer; 2019 Nov; 66(11):e27951. PubMed ID: 31368255
    [No Abstract]   [Full Text] [Related]  

  • 10. Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor.
    Georgin-Lavialle S; Lhermitte L; Suarez F; Yang Y; Letard S; Hanssens K; Feger F; Renand A; Brouze C; Canioni D; Asnafi V; Chandesris MO; Aouba A; Gineste P; Macintyre E; Mansfield CD; Moussy A; Lepelletier Y; Dubreuil P; Hermine O
    Eur J Haematol; 2012 Jul; 89(1):47-52. PubMed ID: 22324351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A case of mast cell leukaemia with exon 9 KIT mutation and good response to imatinib.
    Mital A; Piskorz A; Lewandowski K; Wasąg B; Limon J; Hellmann A
    Eur J Haematol; 2011 Jun; 86(6):531-5. PubMed ID: 21362052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Highly Aggressive de novo Aleukemic Variant of Mast Cell Leukemia Without KIT D816V Mutation.
    Suh MC; Ham JY; Park TI; Moon JH; Suh JS
    Ann Lab Med; 2017 Nov; 37(6):547-549. PubMed ID: 28840997
    [No Abstract]   [Full Text] [Related]  

  • 13. In vivo differentiation of mast cells from acute myeloid leukemia blasts carrying a novel activating ligand-independent C-kit mutation.
    Beghini A; Cairoli R; Morra E; Larizza L
    Blood Cells Mol Dis; 1998 Jun; 24(2):262-70. PubMed ID: 9714703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT.
    Gleixner KV; Mayerhofer M; Sonneck K; Gruze A; Samorapoompichit P; Baumgartner C; Lee FY; Aichberger KJ; Manley PW; Fabbro D; Pickl WF; Sillaber C; Valent P
    Haematologica; 2007 Nov; 92(11):1451-9. PubMed ID: 18024392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of c-kit mutation Asp 816 to Val in microdissected bone marrow infiltrates in a case of systemic mastocytosis associated with chronic myelomonocytic leukaemia.
    Sotlar K; Marafioti T; Griesser H; Theil J; Aepinus C; Jaussi R; Stein H; Valent P; Horny HP
    Mol Pathol; 2000 Aug; 53(4):188-93. PubMed ID: 11040941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. De novo leukemic variant of mast cell leukemia with KIT D816V.
    Bang HI; Park R; Park ES; Choi IH; Kim KH; Shin JW; Choi TY; Han K; Won JH
    Ann Lab Med; 2015 Mar; 35(2):260-2. PubMed ID: 25729733
    [No Abstract]   [Full Text] [Related]  

  • 17. Auer Rods in Chronic Myelomonocytic Leukemia Can Change the Diagnosis.
    Gajendra S; Sahoo RK
    Turk J Haematol; 2015 Sep; 32(3):278-9. PubMed ID: 26376597
    [No Abstract]   [Full Text] [Related]  

  • 18. KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement.
    Kim HJ; Ahn HK; Jung CW; Moon JH; Park CH; Lee KO; Kim SH; Kim YK; Kim HJ; Sohn SK; Kim SH; Lee WS; Kim KH; Mun YC; Kim H; Park J; Min WS; Kim HJ; Kim DH;
    Ann Hematol; 2013 Jan; 92(2):163-71. PubMed ID: 23053179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advanced mast cell disease: an Italian Hematological Multicenter experience.
    Pagano L; Valentini CG; Caira M; Rondoni M; Van Lint MT; Candoni A; Allione B; Cattaneo C; Marbello L; Caramatti C; Pogliani EM; Iannitto E; Giona F; Ferrara F; Invernizzi R; Fanci R; Lunghi M; Fianchi L; Sanpaolo G; Stefani PM; Pulsoni A; Martinelli G; Leone G; Musto P
    Int J Hematol; 2008 Dec; 88(5):483-488. PubMed ID: 19034614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A variant c-KIT mutation, D816H, fundamental to the sequential development of an ovarian mixed germ cell tumor and systemic mastocytosis with chronic myelomonocytic leukemia.
    Mitchell SG; Bunting ST; Saxe D; Olson T; Keller FG
    Pediatr Blood Cancer; 2017 Apr; 64(4):. PubMed ID: 27781377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.